Bionor appoints new Chief Financial Officer

(Oslo, Norway, 6 May 2015) Bionor Pharma ASA (OSE:BIONOR), a peptide vaccine company advancing the potential first therapeutic vaccine towards a functional cure for HIV, today announces the appointment of Jens Krøis as its Chief Financial Officer.

Mr. Krøis has more than 20 years’ financial management experience across the Nordic regions and internationally. His previous roles include Vice President of Business Analysis at AMBU A/S, a leading publically-listed Danish healthcare company, CFO of Global Customer Service at FLSmidth & Co (NASDAQ CO: FLS) and Executive CFO of Connection A/S. Prior to this, Jens was an auditor at KPMG in Copenhagen. He received his Masters in audit at the Copenhagen Business School. Mr. Krøis replaces COO Søren Keller who had been serving as CFO in an interim role.

Bionor’s President and Chief Executive Officer, Dr. David H. Solomon, commented: “Jens brings a wealth of relevant experience to Bionor as CFO. I look forward to working closely with him as we take further steps in growing Bionor in the next phases of our development.”

Jens Krøis added: “Bionor’s progress in HIV vaccine development is inspiring; I am excited by this opportunity to work with the Company and to contribute to its long-term success.” 

Notes for Editors

About Bionor
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company’s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV.

Bionor Pharma’s current clinical development pipeline comprises two vaccine candidates for the treatment of HIV, Vacc-4x and Vacc-C5. Vacc-4x is the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Bionor Pharma’s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through a collaboration with Celgene Corp, is investigating Vacc-4x and romidepsin in the REDUC study.

Bionor is listed on the Oslo stock exchange, under the ticker BIONOR.

More information about Bionor is available at www.bionorpharma.com.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

For more information please contact:
Bionor Pharma ASA
President and Chief Executive Officer David Solomon: Tel +00 47 23 01 09 60

Consilium Strategic Communications
Mary-Jane Elliott / Ivar Milligan / Jessica Hodgson / Hendrik Thys
bionor@consilium-comms.com+44 (0)20 3709 5700